Compare JPMorgan Chase & Co (JPM) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Health Care Select Sector SPDR Fund — how do they compare? JPMorgan Chase & Co trades at $345.3 (market cap $900.78B), while Health Care Select Sector SPDR Fund trades at $160.19. The key difference: JPMorgan Chase & Co pays a 1.77% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| JPM | XLV | |
|---|---|---|
Market Cap | $900.78B | — |
Volume | 10,479,943 | — |
Sector | Financials | — |
52-Week High | $346.91 | $164.48 |
52-Week Low | $282.84 | $129.01 |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $345.23, up 1.21% on the day, with a bullish technical outlook and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside a consensus price target of $372.73, signal positive momentum. Revenue growth is robust, rising to $181.85B in 2025, though net income dipped slightly to $57.05B. The stock benefits from institutional accumulation and media focus on CEO Jamie Dimon's economic insights.
The outlook for JPM remains favorable, driven by earnings resilience and sector leadership, but risks include geopolitical tensions, cybersecurity threats, and volatile cash flows. With a moderate buy rating from analysts and a reasonable P/E of 14.52, the stock offers value, though investors should weigh macroeconomic headwinds against its solid fundamentals.
XLV trades at $159.25, down 1.14% with neutral technical signals overall. The healthcare ETF shows mixed momentum with bullish moving averages but neutral oscillators. Recent news highlights XLV's defensive characteristics amid market volatility, with State Street upgrading healthcare to positive for Q3 2026. The fund's diversified approach offers stability compared to more volatile biotech-focused alternatives.
XLV presents a defensive opportunity with lower costs and steady performance, though upside may be limited in the current cycle. Key risks include patent cliff concerns and sector rotation away from defensive plays if market sentiment improves. The ETF's broad healthcare exposure provides cushion against individual stock volatility while benefiting from pipeline innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
